Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 04 2023 - 7:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2023
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
The first two paragraphs of the press
release attached to this Form 6-K as Exhibit 99.1 are hereby incorporated by reference into the registrant’s Registration
Statements on Form S-8 (File No. 333-229163, 333-248479 and 333-263842) and Form F-3 (File No. 333-228054,
333-238731 and 333-269087), to be a part thereof from the date
on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On January 4, 2023, CollPlant Biotechnologies
Ltd. issued a press release entitled “CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants
Porcine Study and Full Achievement of Objectives”.
Attached hereto and incorporated by reference herein are the following
exhibits:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD. |
|
|
|
|
Date: January 4, 2023 |
By: |
/s/ Eran
Rotem |
|
|
Name: |
Eran Rotem |
|
|
Title: |
Deputy CEO and
Chief Financial Officer |
3
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Sep 2023 to Sep 2024